Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

SIGA Technologies – executive interview

SIGA Technologies – executive interview

SIGA Technologies — 4 videos in collection

More on this equity

SIGA Technologies (Nasdaq: SIGA) is a commercial-stage company focusing on health security. Its lead program is oral TPOXX (tecovirimat), which was approved by the FDA in 2018 for the treatment of smallpox and is active against all orthopoxviruses.

In this video, SIGA chief scientific officer Dennis Hruby discusses SIGA’s work with additional orthopoxviruses, including Monkeypox. Although SIGA’s TPOXX treatment is not yet approved for Monkeypox, the company continues to make progress and recently entered into a collaboration with Oxford University in the United Kingdom to provide TPOXX under an expanded access protocol to treat individuals affected by Monkeypox in the Central African Republic (CAR). Dennis discusses the company’s progress with these diseases and what we can expect to see next from SIGA.

< Previous
Next >

You may also be interested in these:

Healthcare

SIGA Technologies – executive interview

Healthcare

SIGA Technologies and Cipla Therapeutics – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free